Stephen Bagley @StephenBagleyMD · Dec 1, 2025, Dec 1, 2025, 5:34 PM New review out in @NatRevClinOncol on #CARTcells for #GBM and other CNS tumors. Still a lot of work to do, but progress is being made! @DrORourke2 @FosterJb nature.com/articles/s4157…
Stephen Bagley @StephenBagleyMD · Mar 13, 2024, Mar 13, 2024, 10:17 AM Excited to share our early phase 1 results for bivalent #CARTcells in recurrent #glioblastoma. Now online @NatureMedicine. Awesome team effort! @PennMedicine @PennCancer @PennNSG @DrORourke2 nature.com/articles/s4159… www.nature.com Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1... Nature Medicine - In an interim analysis of an ongoing phase 1 trial of CAR T cells targeting EGFR and IL13Ra2 in patients with multifocal, recurrent glioblastoma, intrathecal delivery is feasible...
Stephen Bagley @StephenBagleyMD · Jan 12, 2024, Jan 12, 2024, 11:18 AM Our newest #GBM CART paper now available @NatureCancer. No efficacy signal, but learned a lot about TME thanks to great work of @C_Alanio and others @institut_curie, @parkerici, @PennMedicine, @PennCancer, @MiglioriniDenis, @EJohnWherry, @LabBeatty nature.com/articles/s4301… www.nature.com Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show... Nature Cancer - Bagley et al. conduct a phase 1 trial to study safety and tolerability of CAR T-EGFRvIII cells administered concomitantly with PD-1 inhibition via pembrolizumab in patients with...